PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

Ario Khoshbin, President of Prollenium Medical Technologies Inc., a privately held specialty medical device company, reported today that his firm will continue to record strong year on year gains in revenues and profitability for its 2010 Fiscal Year ending June 30th. Over the past five years, Prollenium has recorded aggregate revenue growth of more than 524% ranking it amongst Canada's fastest growing firms.

This year marks the fourth time that Prollenium's rapid growth has been recognized by PROFIT magazine in its ranking of Canada's Fastest Growing Companies. Once again, Prollenium Medical Technologies is the only Canadian medical device company to make this exclusive list.

"Canada's Fastest-Growing Companies are the poster children for entrepreneurship, innovation and pure tenacity," says Ian Portsmouth, editor of PROFIT. "They demonstrate what it takes to succeed in today's highly competitive, technology-driven global economy."

Commenting on his firm's dynamic growth and development, Mr Khoshbin points out that "Prollenium is engaged in an exciting, ever growing industry sector. With a full line of products to address the needs of the aging face, we have been able to keep up with the demands of this exciting market."

Speaking on his firm's presence in over 60 countries, Mr. Khoshbin continues, "We have capitalized on the success of our popular Revanesse Dermal Filler by forging partnerships with influential pharmaceutical and medical device companies in key foreign markets. These partnerships have enabled us to increase our market share and establish a strong global presence."

Furthermore, Prollenium Medical has recently finished a 118 patient, double blind study that is being used for entry into the lucrative US market.

In addition to the Revanesse Family of Dermal Fillers, Prollenium manufactures a full line of physician grade skin care and will soon be launching a new injectable treatment for pain associated with osteoarthritis as well as novel products for the dermal filler and wound healing markets.

Says Khasha Ighanian, VP "We are very happy with our growth over these past 5 years and by leveraging the efforts of our strong R&D team with our ability to bring new products to the market quickly we are extremely optimistic about the next 5 years as well".




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.